ATZ 1993

Drug Profile

ATZ 1993

Latest Information Update: 01 Jun 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teikoku Hormone
  • Class
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 27 May 2005 Discontinued - Preclinical for Reperfusion injury in Japan (PO)
  • 18 Feb 2003 No development reported - Preclinical for Reperfusion injury in Japan (PO)
  • 17 Feb 2000 A preclinical study has been added to the Ischaemic Heart Disease and Vascular Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top